The Expression And Significance Of P53, ER And PR In Serous Carcinoma And Endometrioid Carcinoma

Objective: Ovarian cancer is one of the most common female reproductive system cancer, due to the lack of early diagnostic tool for ovarian cancer mortality rate ranks first in gynecological malignancies. This experiment studies P53, ER, PR immunohistochemical expression in serous ovarian cancer and endometrial cancer, to understand the role in the development of ovarian cancer to investigate the expression and clinical pathological significance, further clinical diagnosis differential diagnosis and treatment, the prognosis exact laboratory evidence.Methods:Shanxi Tumor Hospital Pathology collection2011-201333cases of ovarian cancer tissue specimens, including20cases of serous carcinoma, endometrial carcinoma in13cases, all of the above cases before surgery no radiotherapy, chemotherapy, hormonal therapy and immunotherapy. Immunohistochemical study En Vision method for detection, detection of P53, estrogen receptor (ER) and progesterone receptor (PR) in the experimental tissue specimens, the counting result of applying statistical software SPSS16.0data analysis, test and pearson correlation analysis to test the level of=0.05, p <0.05, statistically significant analysis of P53, ER, PR in ovarian serous carcinoma and endometrioid carcinoma cases.Results:1. P53expression in ovarian carcinoma: pathological type, the positive expression rate of P53serous carcinoma (80%) than endometrioid carcinoma (38.5%)(p <0.05); histological grading, poorly differentiated carcinoma the positive expression rate of P53(81%) than in well-differentiated carcinoma (33.3%)(p <0.05); clinical stage, the positive expression rate of P53of III-IV (87.5%) than stage I-Ⅱ (41.2%)(p <0.05).2.ER expression in ovarian carcinoma: pathological type, the positive expression rates of endometrial cancer ER (76.9%) than in serous carcinoma (20%)(p <0.05); histological grading, middle and high differentiated carcinoma with positive expression rate of ER were poorly differentiated carcinoma (58.3%,33.3%)(p>0.05); clinical stage, the positive expression rate of I-II of the ER (64.7%) higher than the III-IV period (18.8%)(p <0.05).3.PR expression in ovarian carcinoma: pathological type, the positive expression rates of endometrial cancer PR (69.2%) than in serous carcinoma (15%)(p <0.05); histological grading, middle and high differentiated carcinoma with positive expression rate of PR were poorly differentiated carcinoma (50%,28.6%)(p>0.05); clinical stage, the positive expression rate of I-II of the PR (58.8%) higher than the III-IV period (12.5%)(p <0.05).Conclusion:Comprehensive results of the study, we draw the following conclusions:1.P53expression and pathological type of ovarian cancer, histological grade, clinical stage, higher expression in serous carcinoma, the low degree of differentiation, the expression rate of advanced ovarian cancer.2.ER, PR expression and ovarian histological grade, and pathological type, clinical stage, higher expression in endometrial cancer, ovarian cancer, the later clinical stage, ER, PR positive expression rate lower.3.P53, ER, PR differentially expressed in ovarian serous carcinoma and endometrioid carcinoma, the difference was statistically significant, the three combined detection of antibodies contribute to the diagnosis and differential diagnosis of atypical ovarian cancer lesions.4.Showed a positive correlation between ER and PR, testing ER, PR expression was higher in the later period of the early ovarian cancer, and contribute to the clinical prognosis and guide treatment.